 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the...

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Cardiol Therapeutics (NASDAQ:CRDL  Get Free Report)s stock had its speculative buy rating restated by investment analysts at Leede Jones Gab in a research report issued to...

Cardiol Therapeutics (NASDAQ:CRDL) Given "Speculative Buy" Rating at Leede Jones Gab

Cardiol Therapeutics (NASDAQ:CRDL  Get Free Report)s stock had its speculative buy rating restated by analysts at Leede Jones Gab in a research note issued to investors on...

Leede Jones Gab Reiterates "Speculative Buy" Rating for Cardiol Therapeutics (NASDAQ:CRDL)

Cardiol Therapeutics on track to complete enrollment for acute myocarditis trial six months ahead of schedule...

Cardiol Therapeutics on track to complete enrollment for acute myocarditis trial six months ahead of schedule

Cardiol Therapeutics (NASDAQ:CRDL  Get Free Report) and BioAtla (NASDAQ:BCAB  Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast...

Cardiol Therapeutics (NASDAQ:CRDL) versus BioAtla (NASDAQ:BCAB) Financial Survey

Cantor Fitzgerald reissued their overweight rating on shares of Cardiol Therapeutics (NASDAQ:CRDL Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $3.00 price objective on the stock. Cantor Fitzgerald also issued estimates for...

Cardiol Therapeutics (NASDAQ:CRDL) Earns "Overweight" Rating from Cantor Fitzgerald

Cardiol Therapeutics Inc. (NASDAQ:CRDL  Free Report)  Cantor Fitzgerald increased their FY2023 earnings per share estimates for Cardiol Therapeutics in a research note issued on Monday, August 14th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of...

Cardiol Therapeutics Inc. (NASDAQ:CRDL) to Post FY2023 Earnings of ($0.36) Per Share, Cantor Fitzgerald Forecasts

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of ...

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Cardiol Therapeutics Inc. (NASDAQ:CRDL  Get Free Report) shot up 0.9% on Friday . The company traded as high as $1.22 and last traded at $1.17. 407,324 shares were traded during mid-day trading, an increase of 209% from the average session volume of 131,738 shares. The stock had previously ...

Cardiol Therapeutics (NASDAQ:CRDL) Shares Up 0.9%

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Watchers	1,330
52-Wk Low	$0.45
52-Wk High	$1.24

Market Cap	$58.16M
Volume (M)	89,689.00
52-Wk High	$1.24
52-Wk Low	$0.45

CRDL Cardiol Therapeutics Inc - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals